Mood Disorders

Studies link compassion and wisdom to less loneliness and richer gut microbiome diversity, pointing to gut–brain targets for mental health interventions.

Guidance on psychotropic meds in pregnancy: personalize decisions, coordinate care, and plan early to prevent postpartum relapse.

Planning for prevention of perinatal psychiatric relapse with safer medication options.

Discover APA sessions on OCD therapies, gut-brain microbiome insights, AI, sports psychiatry, and geriatric updates from top clinicians.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

Learn how genetics shape psych med response and dosing.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

Clinicians explore neuroscience-guided off-label prescribing.

Round on the latest news in psychiatry from the last week.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Learn why patients skip psych meds and how to boost adherence with stigma-free dialogue, routine hacks, family support, and deprescribing tips.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Dissect psychodermatology with experts in both fields, from the American Academy of Dermatology 2026.

Bupropion may cause dose-linked tinnitus; this case shows symptoms improve after dose reduction, helping manage depression without stopping treatment.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

Bipolar and spring mania: tips from an expert.

New Sleep in America poll reveals kids fall short on sleep, parents underestimate needs, and family wellbeing suffers.

Experts discuss why early treatment and tailored combos can curb bipolar disorder.

Learn more about ADHD and its intersection with the emerging DMDD space.

Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.

AI romance chatbots turn loneliness into attachment—explore why they feel so real, and mental health risks unfolding now.

See why ketamine boosts outcomes for treatment‑resistant depression.

Unpack hikikomori’s global rise—and what it reveals about psychiatry’s diagnostic limits.

New evidence suggests age-adjusted eGFR cutoffs refine CKD risk, guiding safer lithium use and avoiding unnecessary kidney alarms.